Search results for "colon cancer stage II"
showing 3 items of 3 documents
Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy
2017
Abstract Purpose: There are conflicting results concerning the prognostic value of the CpG island methylator phenotype (CIMP) in patients with nonmetastatic colon cancer. We studied this phenotype in stage III colon cancer characterized for mismatch repair (MMR), RAS, and BRAF status, and treated with adjuvant FOLFOX-based regimen. Experimental Design: Tumor samples of 1,907 patients enrolled in the PETACC-8 adjuvant phase III trial were analyzed. The method used was methylation-specific PCR, where CIMP+ status was defined by methylation of at least 3 of 5 following genes: IGF2, CACNA1G, NEUROG1, SOCS1, and RUNX3. Association between CIMP status and overall survival (OS), disease-free survi…
Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II a…
2013
3524 Background: The MOSAIC study (André T, N Engl J Med, 2004) demonstrated that adding oxaliplatin to adjuvant 5FU and LV improved three-year disease-free survival (DFS) in stage II and III resected CC. Efficacy of FOLFOX4 in pts with dMMR stage III was suggested in a retrospective study (Zaanan A, Ann Oncol 2010). Methods: Of the 2,246 pts included in MOSAIC study, formalin-fixed, paraffin-embedded (FFPE) tissue blocks or slides from 1,019 pts were obtained. Thirty-three samples with insufficient tumor tissue were excluded from this translational study. MMR status was determined by immunohistochemistry (IHC) analysis of the protein products of MLH1, MSH2, PMS2, and MSH6 genes. Results: …
Retrospektīvs pētījums par dzīvildzi resnās zarnas vēža II stadijā, atkarībā no ārstēšanas stratēģijas
2017
Ievads: Adjuvanta ķīmijterapija pacientiem ar diagnosticētu II (UICC) stadijas resnās zarnas vēzi ir apsverama. Pacientu dalījums augsta un zema riska grupās, palīdz izlemt, vai pēc ķirurģiskas ārstēšanas ir indicēta ķīmijterapija, lai gan dzīvildzes ieguvumi nav ne plaši pētīti, nedz arī pierādīti. Tāpēc, autora mērķis šajā pētījumā bija salīdzināt piecu gadu dzīvildzi UICC II stadijas resnās zarnas vēža pacientiem, kuri saņēma adjuvantu ķīmijterapiju, un pacientiem, kuri ķīmijterapiju nesaņēma. Metodes: Dati par pacientiem ar II stadijas resnās zarnas vēzi, tika iegūti Paula Stradiņa Klīniskās universitātes slimnīcā Rīgā, Latvijā, Onkoloģijas klīnikā. Diagnozes apstiprināšanas laiks no 20…